- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Dr Brandon Shank: Biosimilar Naming and Suffixes
Brandon Shank, PharmD, MPH, BCOP, Clinical Pharamcy Specialist, discusses the merits of the current biosimilar naming system.
Transcript:
Could 4-letter suffixes to the names of biosimilars create confusion?
I think one benefit of the naming system is that you know what the reference product is. I think some clinicians, pharmacists included, and patients may assume interchangeability, which may not be inferred by the naming system. I think it is important to have a way to differentiate these products so that you can know which ones are interchangeable, so that ones with different indications will also be recognized and not be used for the wrong indication. Also, dosing and administration differences in products may also be assumed with the naming system, which is why the suffix will be helpful in those situations. I also believe that with this naming system, they need to differentiate the products in the computer order systems and be able to have adverse event reporting that distinctly identifies them, which the naming system will with the current suffix system.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
